Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2016-05-12

Clinical Trial Update: Study of Lenalidomide in Previously Untreated, Symptomatic Chronic Lymphocytic Leukemia (CLL) [Phase 2]

View source ↗

Summary

A Phase 2 study of lenalidomide in previously untreated, symptomatic chronic lymphocytic leukemia was terminated. Results were posted in 2016.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Revlimid (lenalidomide)

Snippet

Sponsor: University Health Network, Toronto | Conditions: Chronic Lymphocytic Leukaemia | Phase 2 | Status: TERMINATED | Results posted: 2016-05-12